Cart
sales@molnova.com
AMG-900
CAS No. 945595-80-2
AMG-900( AMG 900 | AMG900 )
Catalog No. M16773 CAS No. 945595-80-2
AMG-900 (AMG900) is a potent, highly selective, orally bioavailable pan-Aurora kinase inhibitor with IC50 of 5, 4 and 1 nM for Aurora A, B and C, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 59 | In Stock |
|
| 5MG | 104 | In Stock |
|
| 10MG | 178 | In Stock |
|
| 25MG | 296 | In Stock |
|
| 50MG | 443 | In Stock |
|
| 100MG | 645 | In Stock |
|
| 500MG | 1341 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAMG-900
-
NoteResearch use only, not for human use.
-
Brief DescriptionAMG-900 (AMG900) is a potent, highly selective, orally bioavailable pan-Aurora kinase inhibitor with IC50 of 5, 4 and 1 nM for Aurora A, B and C, respectively.
-
DescriptionAMG-900 (AMG900) is a potent, highly selective, orally bioavailable pan-Aurora kinase inhibitor with IC50 of 5, 4 and 1 nM for Aurora A, B and C, respectively; displays excellent specificity in a panel of 26 kinases with exception of p38α and TYK2 (IC50=53 and 220 nM), also exhibits high affinity (Kd< 50 nM) with DDR1, DDR2, and LTK receptor tyrosine kinases; blocks the proliferation of multiple human tumor cell lines including cell lines resistant to paclitaxel, AZD1152, MK-0457, and PHA-739358 with IC50 of 0.7-5.3 nM; blocks the phosphorylation of histone H3 in a dose-dependent manner and significantly inhibits the growth of HCT116 tumor xenografts.Blood Cancer Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAMG 900 | AMG900
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAuroraA|AuroraB|AuroraC|p38α|Tyk2
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number945595-80-2
-
Formula Weight503.6
-
Molecular FormulaC28H21N7OS
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC1=CSC(C2=NN=C(NC3=CC=C(OC4=NC=CC=C4C5=NC(N)=NC=C5)C=C3)C6=C2C=CC=C6)=C1
-
Chemical Name1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(4-methyl-2-thienyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Geuns-Meyer S, et al. J Med Chem. 2015 Jul 9;58(13):5189-207.
2. Juan G, et al. J Transl Med. 2014 Nov 4;12:307.
3. Paller CJ, et al. Cancer Med. 2014 Oct;3(5):1322-35.
4. Payton M, et al. Cancer Res. 2010 Dec 1;70(23):9846-54.
molnova catalog
related products
-
Aurora A-IN-10
A potent, highly selective Aurora A inhibitor with IC50 of 3.4 nM; displays >1,000-fold selectivity over Aurora B (IC50=3.4 uM) or CDKs.
-
Pilaralisib
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).
-
ZM-447439
ZM-447439 is a potent, selective dual Aurora A and Aurora B inhibitor with IC50 of 110 and 130 nM, respectively.
